Y Chen1, P Rubin, J Williams, E Hernady, T Smudzin, P Okunieff. 1. Department of Radiation Oncology, James P. Wilmot Cancer Center, University of Rochester, 601 Elmwood Ave., Box 647, Rochester, NY 14642, USA. ychen@radonc.medinfo.rochester.edu
Abstract
PURPOSE: We report results from a clinical research protocol investigating circulating pro-inflammatory cytokines (interleukin-6 [IL-6] and tumor necrosis factor alpha [TNFalpha]) in relation to radiation pulmonary injury. METHODS AND MATERIALS: In a protocol for cytokine measurement, 25 patients had clinical follow-up longer than 12 months, and 24 had serial cytokine data. Serial plasma specimens before, during, and after thoracic radiotherapy were analyzed for IL-6 and TNFalpha using enzyme-linked immunosorbent assay (ELISA). Radiation pulmonary injury was defined using National Cancer Institute Common Toxicity Criteria. RESULTS: Of the 24 patients, 6 had Grade 1 pneumonitis, and 13 had Grade 2 pneumonitis. There was no Grade 3/4 pneumonitis. Median time of radiation pneumonitis was between 8 and 12 weeks post-therapy. IL-6 levels before, during, and after thoracic radiation therapy were significantly higher in those who developed pneumonitis. In contrast, we did not detect a significant correlation between plasma TNFalpha and radiation pneumonitis. CONCLUSIONS: High pretreatment plasma levels of IL-6 predisposed patients to the risk of radiation pneumonitis. Pretreatment IL-6 level may serve as a predictor for radiation pneumonitis. Serial plasma IL-6 was consistently higher for the pneumonitis group. The role of IL-6 in the cytokine cascades that promote radiation pulmonary injury deserves further investigation.
PURPOSE: We report results from a clinical research protocol investigating circulating pro-inflammatory cytokines (interleukin-6 [IL-6] and tumor necrosis factor alpha [TNFalpha]) in relation to radiation pulmonary injury. METHODS AND MATERIALS: In a protocol for cytokine measurement, 25 patients had clinical follow-up longer than 12 months, and 24 had serial cytokine data. Serial plasma specimens before, during, and after thoracic radiotherapy were analyzed for IL-6 and TNFalpha using enzyme-linked immunosorbent assay (ELISA). Radiation pulmonary injury was defined using National Cancer Institute Common Toxicity Criteria. RESULTS: Of the 24 patients, 6 had Grade 1 pneumonitis, and 13 had Grade 2 pneumonitis. There was no Grade 3/4 pneumonitis. Median time of radiation pneumonitis was between 8 and 12 weeks post-therapy. IL-6 levels before, during, and after thoracic radiation therapy were significantly higher in those who developed pneumonitis. In contrast, we did not detect a significant correlation between plasma TNFalpha and radiation pneumonitis. CONCLUSIONS: High pretreatment plasma levels of IL-6 predisposed patients to the risk of radiation pneumonitis. Pretreatment IL-6 level may serve as a predictor for radiation pneumonitis. Serial plasma IL-6 was consistently higher for the pneumonitis group. The role of IL-6 in the cytokine cascades that promote radiation pulmonary injury deserves further investigation.
Authors: Ronny Kalash; Hebist Berhane; Jeremiah Au; Byung Han Rhieu; Michael W Epperly; Julie Goff; Tracy Dixon; Hong Wang; Xichen Zhang; Darcy Franicola; Ashwin Shinde; Joel S Greenberger Journal: In Vivo Date: 2014 Mar-Apr Impact factor: 2.155
Authors: Matthew H Stenmark; Xu-Wei Cai; Kerby Shedden; James A Hayman; Shuanghu Yuan; Timothy Ritter; Randall K Ten Haken; Theodore S Lawrence; Feng-Ming Spring Kong Journal: Int J Radiat Oncol Biol Phys Date: 2012-10-01 Impact factor: 7.038
Authors: Weiliang Huang; Jianshi Yu; Jace W Jones; Claire L Carter; I Lauren Jackson; Zeljko Vujaskovic; Thomas J MacVittie; Maureen A Kane Journal: Health Phys Date: 2019-04 Impact factor: 1.316
Authors: Dirk De Ruysscher; Jianyue Jin; Tim Lautenschlaeger; Jin-Xiong She; Zhongxing Liao; Feng-Ming Spring Kong Journal: Transl Lung Cancer Res Date: 2017-12